Orchid invests in Diakron
This article was originally published in Scrip
Executive Summary
Orchid Chemicals and Pharmaceuticalshas acquired majority control in Diakron Pharmaceuticals, the US drug development firm that has an exclusive licence for an investigational oral anticoagulant drug candidate discovered and developed through Phase I by Merck & Co. Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.
You may also be interested in...
Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla's COO Steps Down
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Newbie Remogliflozin Gives Competition A Run For Their Money
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.
Need a specific report? 1000+ reports available
Buy Reports